Accenture plc Posts Profit-to-Profit Growth on Revenue and Net Income Across Both Reporting Windows

Bottom line

- Revenues for the three-month reporting period rose versus the prior-year comparative, with the prior-year period remaining positive and the current period remaining positive. - Revenues for the nine-month year-to-date period rose versus the prior-year comparative, with the prior-year period remaining positive and the current period remaining positive. - Operating Income (Loss) for the three-month reporting period rose versus the prior-year comparative, with the prior-year period a profit and the current period a profit.

- Operating Income (Loss) for the nine-month year-to-date period rose versus the prior-year comparative, with the prior-year period a profit and the current period a profit. - Net Income (Loss) Attributable to Parent for the three-month reporting period rose versus the prior-year comparative, with the prior-year period a profit and the current period a profit. - Net Income (Loss) Attributable to Parent for the nine-month year-to-date period rose versus the prior-year comparative, with the prior-year period a profit and the current period a profit.

- Earnings Per Share, Diluted for the three-month reporting period rose versus the prior-year comparative, with the prior-year period a profit and the current period a profit. - Earnings Per Share, Diluted for the nine-month year-to-date period rose versus the prior-year comparative, with the prior-year period a profit and the current period a profit. - The filing evidence does not attribute this change to any single cause.

S. GAAP, which management states should be read alongside the annual report for the fiscal year ended August (omitted) filed on Form (omitted) with the SEC. - The filing evidence contains no peer or industry comparison, so any cross-issuer benchmarking must wait for a later data point: The filing evidence contains no peer or industry comparison.

- The filing evidence does not disclose segment-level detail for these dimensions in the cited note window beyond the segment-reporting reference in Note 12, so section one cannot rest any claim on segment composition today: The filing evidence does not disclose segment-level detail for this dimension. - A reader wanting a parallel example of a profit-to-profit interim print on both windows can compare against the earlier Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows write-up to confirm the same directional pattern, while the comparable Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows entry documents the identical profit-to-profit shape at a different issuer.

Financial performance

- Revenues for the three-month period were $18,718,144,000 USD, compared with $17,727,871,000 USD in the prior-year three-month window; both periods were profitable with revenue higher than the prior period. - Revenues for the nine-month year-to-date period were $55,504,334,000 USD, compared with $52,076,717,000 USD for the prior-year nine-month window; the year-to-date total was also higher than the prior period. - Operating Income (Loss) for the three-month period was $3,175,298,000 USD, compared with $2,982,782,000 USD in the prior-year three-month window; both periods reflected a profit, with operating income higher than the prior period.

- Operating Income (Loss) for the nine-month year-to-date period was $8,542,543,000 USD, compared with $8,175,973,000 USD for the prior-year nine-month window; both periods were profitable with operating income higher than the prior period. - Net Income (Loss) Attributable to Parent for the three-month period was $2,338,989,000 USD, compared with $2,197,501,000 USD in the prior-year three-month window; both periods reflected a profit, with net income higher than the prior period. - Net Income (Loss) Attributable to Parent for the nine-month year-to-date period was $6,375,789,000 USD, compared with $6,264,470,000 USD for the prior-year nine-month window; both periods were profitable with net income higher than the prior period.

49 per diluted share USD/SHARES in the prior-year three-month window; both periods reflected a profit, with diluted EPS higher than the prior period. 9 per diluted share USD/SHARES for the prior-year nine-month window; both periods were profitable with diluted EPS higher than the prior period. S.

GAAP, with the unaudited interim Consolidated Financial Statements reflecting all adjustments of a normal, recurring nature that management considers necessary for a fair presentation of the interim periods. - The interim results for the three- and nine-month windows covered here are described in the source narrative as not necessarily indicative of results that may be expected for the full fiscal year ending August (omitted), and the statements should be read together with the most recent Annual Report on Form referenced in the filing.

- Revenue recognition is tied to remaining performance obligations under Topic (omitted), with only the non-cancelable portion of terminable contracts included and variable consideration recognized only when a significant reversal is not probable; contract-estimate adjustments related to prior-period performance obligations were described as immaterial for both windows. - Allowance for credit losses on client receivables and contract assets was reported as of May (omitted) and August (omitted), with the change attributed in the source narrative to specific client reserves, gross receivables and contract-asset balances, and immaterial write-offs.

- Management is evaluating pending ASU updates covering income-tax disclosures, disaggregation of income-statement expenses, and targeted improvements to internal-use-software accounting; adoption timing ranges from the next annual fiscal year to a subsequent interim fiscal year, and the source narrative states only the tax-disclosures ASU is not expected to affect financial position or results of operations. - The filing evidence does not attribute this change to any single cause. - Management did not provide a quantitative forward outlook in this filing's interim statements, and the filing evidence contains no peer or industry comparison.

The filing evidence contains no peer or industry comparison. - Readers comparing multi-window filings can reference the prior Lizely Finance earnings analysis on REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing for a parallel profit-to-profit structure across two reporting windows.

Operating drivers and segments

The filing is 10-Q period-ended-2026-05-31 filed under accession 0001467373-26-000032 by Accenture plc (ACN). Segment-level disaggregated revenue is not reproduced inside the income-statement or equity-statement excerpts that the filing evidence surfaces; instead, the registrant points readers to the cited segment-reporting note for the broken-out revenue view. Operating Income (Loss) for the three-month period of the three months ended May 31, 2026 was $3,175,298,000, compared with $2,982,782,000 for the three months ended May 31, 2025, and Operating Income (Loss) for the nine-month year-to-date window of the nine months ended May 31, 2026 was $8,542,543,000, compared with $8,175,973,000 for the nine months ended May 31, 2025. Revenues for the same three-month window of the three months ended May 31, 2026 were $18,718,144,000 versus $17,727,871,000 for the three months ended May 31, 2025, and for the nine-month window of the nine months ended May 31, 2026 revenues were $55,504,334,000 versus $52,076,717,000 for the nine months ended May 31, 2025. The cross-check between top line and operating profit shows the top line moving higher in both windows and operating income also moving higher in both windows, with the nine-month operating margin staying roughly flat against the prior nine-month window and the three-month operating margin also appearing roughly flat against its prior-year quarter, though no explicit margin percentage is disclosed in the cited excerpts.

The filing evidence does not contain a management discussion-of-results passage in this section's excerpts, so there is no attributable narrative on demand, pricing, utilization, geographic mix or other operating drivers beyond the segment-reporting cross-reference. The basis-of-presentation language confirms only that the unaudited interim statements were prepared under U.S. GAAP per SEC quarterly-report rules, that estimates and assumptions affect reported amounts, and that results for the three and nine months ended May (omitted) are not necessarily indicative of the full fiscal year. The equity-method and redeemable-noncontrolling-interest notes address the equity-statement line rather than the operating drivers behind revenue or operating income.

Independent cross-checks against peer or industry benchmarks, segment mix detail beyond the cited note, or any management-prepared bridge from prior-year operating income to current operating income are not present in the excerpts that this section is allowed to rely on. Readers wanting the services-mix view should follow the in-filing pointer to Note 12 (Segment Reporting) for disaggregated revenues. For an external cross-check of how a single-quarter top-line and net-income print can move together in the same direction, see REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in the reporting period Filing.

The filing evidence does not attribute this change to any single cause.

Cash flow and capital

The Accenture plc filing under 10-Q for period-ended-2026-05-31 (accession 0001467373-26-000032) presents the consolidated statements of cash flows for the nine-month year-to-date period and the prior-year comparative. Reported facts on operating, investing and financing cash flows are stated, alongside capital expenditures and share-repurchase outflows, each tied to its catalog key.

REPORTED FACTS (FROM THE FILING): - Net Cash Provided by (Used in) Operating Activities was $9,267,947,000 USD for the nine months ended May 31, 2026, compared with $7,560,252,000 USD for the nine months ended May 31, 2025. - Net Cash Provided by (Used in) Investing Activities was -$3,452,305,000 USD for the nine months ended May 31, 2026, compared with -$1,248,360,000 USD for the nine months ended May 31, 2025. - Net Cash Provided by (Used in) Financing Activities was -$7,090,560,000 USD for the nine months ended May 31, 2026, compared with -$1,673,260,000 USD for the nine months ended May 31, 2025. - Payments to Acquire Property, Plant, and Equipment were $492,491,000 USD for the nine months ended May 31, 2026, compared with $492,124,000 USD for the nine months ended May 31, 2025. - Payments for Repurchase of Common Stock were $5,193,277,000 USD for the nine months ended May 31, 2026, compared with $4,145,609,000 USD for the nine months ended May 31, 2025.

On the balance-sheet side at the balance sheet date of May 31, 2026, the filing records Cash and Cash Equivalents at Carrying Value of $10,165,245,000 USD, Accounts Receivable (after Allowance for Credit Loss) of $13,992,742,000 USD, and Accounts Payable (Current) of $3,176,740,000 USD.

The cited notes describe contract balances as the bridge between revenue recognition and cash collection, separating Receivables (rights conditional only on the passage of time) from Contract assets (rights conditional on additional factors). Deferred revenues arise when billing or cash collection precedes revenue recognition, and they also include amounts for transition or set-up activities on managed services contracts, which are deferred and recognized as the services are provided. The filing notes that changes in contract asset and liability balances during the nine-month period were a product of normal business activity and were not materially impacted by other factors.

ANALYST INFERENCE (year-over-year, only the authorized direction may be asserted): - Operating cash flow for the nine-month period was higher than the prior-year comparative (authorized direction: increase; current positive, prior positive; transition: positive to positive). - Investing cash flow for the nine-month period decreased versus the prior-year comparative (authorized direction: decrease; current negative, prior negative). - Financing cash flow for the nine-month period decreased versus the prior-year comparative (authorized direction: decrease; current negative, prior negative). - Capital expenditures increased relative to the prior-year comparative (authorized direction: increase; current positive, prior positive). - Share repurchases increased relative to the prior-year comparative (authorized direction: increase; current positive, prior positive).

COUNTER-EVIDENCE / QUALIFIERS: - All five year-over-year claims rest on the same limited evidence: the nine-month comparative figures. No quarterly cash-flow series is disclosed in this filing, so trends within the year cannot be reconstructed from the filing evidence. - The investing and financing cash-flow values are both negative for the current and prior periods; the authorized "decrease" reflects a larger outflow magnitude in the current period. - Capital intensity and capital return are visible only as two line items in the cash-flow statement; the filing does not isolate free cash flow, dividends, or proceeds from debt issuance as separate lines in the supplied narrative.

- The drivers of the lower investing outflow, lower financing outflow, higher operating inflow, higher capex and higher repurchases are not stated. The filing evidence does not attribute this change to any single cause. - Peer or industry cash-flow comparisons are not provided. The filing evidence contains no peer or industry comparison. - The composition of receivables aging, the geographic split of deferred revenues, and the residual-performance-obligation roll-forward are not detailed in the supplied narrative.

For readers weighing capital-return durability, the year-over-year rise in repurchases together with higher capex underscores continued reinvestment alongside return-of-capital — a pattern comparable to the recent REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended Filing, where higher operating cash conversion similarly supported both organic investment and capital return.

Peer and historical context

Reported facts (from the filing): - Revenues were $55,504,334,000 USD for the nine-month year-to-date period the nine months ended May 31, 2026. - Revenues were $18,718,144,000 USD for the three-month reporting period the three months ended May 31, 2026. - Revenues were $52,076,717,000 USD for the prior-year comparative period the nine months ended May 31, 2025. - Revenues were $17,727,871,000 USD for the prior-year comparative period the three months ended May 31, 2025. - Operating Income (Loss) was $8,542,543,000 USD for the nine-month period and $3,175,298,000 USD for the quarter, versus $8,175,973,000 USD and $2,982,782,000 USD respectively in the prior-year comparatives. - Net Income (Loss) Attributable to Parent was $6,375,789,000 USD for the nine-month period and $2,338,989,000 USD for the quarter, versus $6,264,470,000 USD and $2,197,501,000 USD respectively. - Net Cash Provided by (Used in) Operating Activities was $9,267,947,000 USD for the nine-month period, compared with $7,560,252,000 USD in the prior-year comparative.

Management explanations: The filing's narrative does not present a side-by-side revenue composition walk-through for the current year versus prior year, nor does it benchmark the company against a named peer set or industry index. Disaggregated revenue context is provided through reference to the cited note (Segment Reporting), but management does not articulate within the quoted material why the year-over-year comparisons moved.

Analyst inference: - On both reporting windows (the three-month and the nine-month year-to-date period), the revenue base was higher than the prior-year comparative, consistent with continued top-line expansion. The authorized comparison registers revenues as higher on both windows. - Profitability measures (Operating Income and Net Income Attributable to Parent) were also higher than the prior-year comparative on both windows, and the underlying transitions remained profit to profit on each window, suggesting that margin character was preserved while absolute levels expanded. - Cash generation from operations was higher than the prior-year nine-month comparative, indicating that the operating-cash engine was at least as productive in absolute terms relative to the prior window. - Because the filing does not enumerate a peer cohort, no cross-company benchmark can be drawn from the filing evidence. Any attempt to position this performance against consulting or IT-services peers, or against broader market indices, lies outside the material at hand.

- The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The filing evidence contains no peer or industry comparison; therefore no counter-position from competitors can be cited and no relative outperformance or underperformance can be asserted. - Within the filing's quoted narrative, contract-estimate adjustments tied to performance obligations satisfied in prior periods were described as immaterial for both the three- and nine-month windows, so no material favourable or unfavourable revision to prior-period estimates is evident that would complicate the year-over-year read. - Receivables and contract-asset balances as of the period-end reference points are disclosed in the cited balance-sheet context, but no quantitative comparison against the prior comparable date is restated in the quoted evidence, limiting a countervailing balance-sheet signal.

Scenario analysis

- In the base case, top-line and bottom-line performance continue along the trajectory the latest period reports. Revenues for the three months ended May 31, 2026 print at $18,718,144,000 USD, sitting above $17,727,871,000 USD for the three months ended May 31, 2025, and Revenues for the nine months ended May 31, 2026 reach $55,504,334,000 USD versus $52,076,717,000 USD for the nine months ended May 31, 2025. - Net Income (Loss) Attributable to Parent for the three months ended May 31, 2026 is reported at $2,338,989,000 USD, higher than $2,197,501,000 USD for the three months ended May 31, 2025, and the nine-month figure stands at $6,375,789,000 USD, higher than $6,264,470,000 USD for the nine months ended May 31, 2025. Both windows stay in a profit-to-profit transition with the authorized year-over-year increase intact. - This is the middle path the filing itself anchors, and the only profitability lens the filing evidence supplies directly.

- The upside case keeps the same revenue and net income direction but stretches it, with Revenues for the three months ended May 31, 2026 printing meaningfully above $17,727,871,000 USD and Net Income (Loss) Attributable to Parent for the three months ended May 31, 2026 clearing $2,197,501,000 USD by a wider gap. - Over the longer window, Revenues for the nine months ended May 31, 2026 extend further past $52,076,717,000 USD and Net Income (Loss) Attributable to Parent for the nine months ended May 31, 2026 widens its lead over $6,264,470,000 USD, still in a profit-to-profit transition. - The filing evidence does not disclose segment-level detail behind that acceleration, so the size of the upside beyond the reported direction cannot be quantified from this filing alone — The filing evidence does not disclose segment-level detail for this dimension. applies on that point, and The filing evidence contains no peer or industry comparison. applies on any cross-company check. - For context on how a peer accelerated in a similar interim window, see REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing.

- In the downside case the reported increase still holds, but Revenues for the three months ended May 31, 2026 narrow toward $17,727,871,000 USD, and Net Income (Loss) Attributable to Parent for the three months ended May 31, 2026 compress toward $2,197,501,000 USD — both still in a profit-to-profit transition rather than flipping to a loss. - The nine-month picture would show Revenues for the nine months ended May 31, 2026 closer to $52,076,717,000 USD, with Net Income (Loss) Attributable to Parent for the nine months ended May 31, 2026 trimming its lead over $6,264,470,000 USD. - the filing does not isolate a single driver for the prior-year base, so any softness cannot be tied to a specific cost or volume line here — The filing evidence does not attribute this change to any single cause. applies, and The filing evidence does not disclose segment-level detail for this dimension. rules out a segment-by-segment attribution in this section.

Risks and what to watch

- Reported facts: The interim filing for Accenture plc under 10-Q for period-ended-2026-05-31 (accession 0001467373-26-000032, CIK 0001467373, ticker ACN) shows Revenues of $18,718,144,000 for the three months ended May 31, 2026 and $55,504,334,000 for the nine months ended May 31, 2026, with prior-year comparatives of $17,727,871,000 and $52,076,717,000. Net Income (Loss) Attributable to Parent was $2,338,989,000 for the three months ended May 31, 2026 and $6,375,789,000 for the nine months ended May 31, 2026, against $2,197,501,000 and $6,264,470,000.

- Management explanations: The cited note describes deferred revenue mechanics on managed services contracts — payments for transition or set-up activities are deferred and recognized as the services are provided, with related costs also deferred and expensed over the service period. Management states that deferred transition costs are generally recoverable under the contract in the event of early termination and are monitored regularly for impairment, with impairment losses recorded when projected remaining undiscounted operating cash flows of the related contract are not sufficient to recover the carrying amount of contract assets.

Management also characterizes the period change in contract asset and liability balances as normal business activity not materially impacted by any other factors. - Analyst inference: Both revenues and net income registered as profit-to-profit growth on the quarter and nine-month windows, consistent with the authorized transitions. Contract liability behavior in the cited note does not point to any unusual acceleration or release of deferred revenue beyond ordinary service recognition.

Diluted EPS mechanics in the cited note exclude an immaterial amount of restricted stock units that were antidilutive, which is a routine computational disclosure rather than a signal of share count stress. - Counter-evidence and downside risk: Deferred transition costs depend on customer contracts remaining in force, so any early termination outside the recoverable scenario could expose the carrying amount to impairment — the cited note expressly identifies this as the impairment trigger, even though management indicates recoverability is the norm.

Noncontrolling-interest exchangeable shares referenced in the cited note introduce a small structural reconciliation between consolidated net income and the parent-only figure; the cited note explains that the income effect on diluted EPS excludes "Net income attributable to noncontrolling interests - other" because those shares are not redeemable or exchangeable for Accenture plc Class A ordinary shares. The filing evidence does not attribute this change to any single cause. - Unknowns: The filing evidence does not disclose segment-level detail for these revenue and income movements.

The filing evidence does not disclose segment-level detail for this dimension. The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison.

The pro forma effects of recent acquisitions are described in the cited note as not material, but no quantified disclosure of acquisition contribution is provided. Forward guidance, book-to-bill commentary, and pricing or utilization trends are not in the filing evidence for this section. - Metrics to watch next period: Whether the current-period growth in Revenues and Net Income (Loss) Attributable to Parent continues at a similar pace, whether deferred revenue balances expand or contract relative to revenue (a leading indicator of forward service obligations), and whether any transition-cost impairment is recorded.

A useful cross-check for readers triangulating profit-to-profit growth stories is Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows, which applies a similar lens to a different issuer.